Nicolas Musi
Endocrinologist and aging researcher who directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center at Cedars-Sinai, and who studies how aging drives insulin resistance, frailty and senescence
Director, Division of Endocrinology, Diabetes and Metabolism, and Director, Diabetes and Aging Center, Cedars-Sinai Medical Center (since 2022) · Kathi and Gary Cypres Chair in Diabetes Research (2024) · earlier at the Barshop Institute for Longevity and Aging Studies, UT Health San Antonio, and South Texas Veterans Health Care System (PubMed affiliation 2018)
Diabetes and Aging Center, Cedars-Sinai Medical Center (Los Angeles, California, USA) ↗
Portrait: Cedars-Sinai
Nicolas Musi is a co-author of the 2018 trial in this Atlas (KRA2018), a randomized placebo-controlled pilot study in 25 healthy adults aged 70 to 95. Daily low-dose rapamycin for at least 8 weeks was generally well tolerated, with small changes in red blood cell measures and no rise in blood glucose or insulin resistance. That last point matters because rapamycin can disturb sugar handling in mice. The trial was small and short.
At the time Musi worked at the Barshop Institute for Longevity and Aging Studies and the Department of Medicine of UT Health San Antonio, and at the South Texas Veterans Health Care System. Musi's research covers how aging affects metabolism and cells in diabetes, obesity and sarcopenia (age-related muscle loss), the effects of exercise on glucose and fat metabolism, and cellular senescence, the state in which damaged cells stop dividing but stay active.
Musi moved to Cedars-Sinai Medical Center in Los Angeles in 2022. There Musi directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center, and in 2024 became the first holder of the Kathi and Gary Cypres Chair in Diabetes Research. The current work includes a clinical trial testing whether removing senescent cells improves glucose metabolism and physical function. Musi is an elected member of the Academy for Health and Lifespan Research.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. KRA2018 Co-author: part of the San Antonio team that ran the pilot safety trial of daily rapamycin in healthy adults aged 70 to 95. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Nicolas Musi.
ShowHide
- Adriana D. Benavides Immunologist who worked at UT Health San Antonio and the Children's Hospital of Philadelphia, and a co-author of the first small safety trial of rapamycin in healthy older people
- Dean L. Kellogg Jr. A geriatrician who co-leads clinical trials of rapamycin in older adults at the Barshop Institute, with a focus on safety and cardiovascular effects.
- Ellen Kraig Immunologist at UT Health San Antonio who studies how aging changes immune regulation and who led the first small safety trial of rapamycin in healthy older people at the Barshop Institute
- Martin A. Javors Pharmacologist and professor at UT Health San Antonio who directs an analytical laboratory for biochemical and drug measurements, and a co-author of rapamycin studies in mice and in older people
- Qianqian Liu Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.